These downloadable slides by Dr. Neal D. Shore, MD, FACS are on the topic of management of adverse effects in ADT for men with prostate cancer. These slides were presented at a satellite symposium presented in conjunction with the AUA Annual Meeting held on Sunday, May 14, 2017 entitled “Navigating the Adverse Effects of ADT: Improving Patient Outcomes”.
- HOME
- MEETINGS
- AdMeTech Global Summit
- Future Directions in Urology Symposium
- Innovations in Urologic Practice
- International Bladder Cancer Expert Forum
- International Bladder Cancer Update
- International Prostate Cancer Update
- Perspectives in Urology: Point-Counterpoint
- Ralph E. Hopkins Urology Seminar
- Southwest Prostate Cancer Symposium
- Urology Today
- CONTENT & COMMENTARIES
- LEARNING CENTERS
- INDUSTRY PERSPECTIVE
- Industry Perspective: AR-V7 Testing for Men with Advanced Stage Prostate Cancer
- Industry Perspective: ConfirmMDx and Improving the Identification of Men at Risk for Clinically Significant Prostate Cancer
- Industry Perspective: The Oncotype DX Genomic Prostate Score Assay Test
- Industry Perspective: Panel Discussion on Cxbladder Genomic Urine Test for Bladder Cancer
- The Role of URO17™ in the Diagnosis and Management of Bladder Cancer
- Industry Perspective: Developing the Most Sensitive Urine Test for Bladder Cancer
- FACULTY
Select Page